仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma （RRMM）. Elotuzumab results in improved response and outcome when combined with other antimyeloma agents